Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities (2012 - 2026)

Vanda Pharmaceuticals has reported Other Non-Current Liabilities for 14 years, with the latest figure at $10.1 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 9.54% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (up 9.54% YoY) and the FY2025 annual result came in at $9.5 million, down 0.56% from the prior year.
• Other Non-Current Liabilities climbed to $10.1 million in Q1 2026 per VNDA's latest filing, from $9.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $11.0 million in Q3 2025 and troughed at $1.0 million in Q1 2022.
• A 5-year average of $7.7 million and a median of $8.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 61.09% in 2022, then jumped 540.08% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $6.8 million in 2022, then advanced by 29.81% to $8.8 million in 2023, then gained by 8.61% to $9.6 million in 2024, then retreated by 0.56% to $9.5 million in 2025, then grew by 6.23% to $10.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $10.1 million, $9.5 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.